Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-blocker or 5-ARI Withdrawal in BPH
NCT05023824Phase 3Unknown
- Sponsor
- Gangnam Severance Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in benign prostatic hyperplasia (BPH) (3 arms), sponsored by Gangnam Severance Hospital. Primary endpoint: International Prostate Symptom Score at 18 months. Status: unknown.
02
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT05023824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05023824.